期刊
HELIYON
卷 9, 期 6, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.heliyon.2023.e16664
关键词
SARS-CoV2; Sotrovimab; Non human primate; BQ; 1
The SARS-CoV2 Omicron variants have acquired new Spike mutations that make them resistant to most currently available monoclonal antibody treatments, limiting options for severe Covid-19 patients. However, recent data suggests that Sotrovimab may still be partially effective against the BA.5 variants, including BQ.1.1. In a non-human primate challenge model, Sotrovimab showed full efficacy in inhibiting BQ.1.1 viral replication as measured by RT-qPCR.
The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could retain partial activity against recent omicron sub-lineage such as BA.5 variants, including BQ.1.1. Here we report full efficacy of Sotrovimab against BQ.1.1 viral replication as measure by RT-qPCR in a non-human primate challengemodel.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据